Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology
Citryll announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance.
Read moreSynergy between biopharma and academia
Pivot Park firmly believes in the importance of collaboration between biotech and academia, and therefore strongly supports its partners with its broad “knowledge network”, which includes the Institute for Complex Molecular Systems (ICMS) at the Eindhoven University of Technology (TU/e).
Read morePharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa
Pharming announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals for the distribution of RUCONEST® (Conestat alfa) in the Middle East and North Africa.
Read moreGlycostem obtained the Tissue Bank License, to support the production of our lead investigational product oNKord®.
Currently oNKord® is produced with cord blood from UK. The Tissue Bank License makes it possible to continue production after the Brexit transition period, to use raw materials from other countries outside the EU, for example US, in the future. They are continuing treating AML patients in the oNKord phase I/phase II clinical trial.
Read moreWelkom Van Iersel Luchtman Advocaten
Vanaf mei 2021 is ons advocatenkantoor aangesloten bij het Pivot Park. Als satellite tenant hebben we geen vast kantoor, maar zijn we altijd bereikbaar en beschikbaar om je (virtueel) te ontmoeten als daar behoefte aan is.
Read moreSynaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies
Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company.
Read moreCitryll announced that it has recently secured three grant of patents
Citryll is pleased to announce that it has recently secured grant of patents in China (in March 2021), in Australia (in May 2021), and in the USA (in July 2021) relating to the use of therapeutic Anti-Citrullinated Protein Antibodies (tACPAs) to treat one of our lead indications, idiopathic pulmonary fibrosis (IPF).
Read morePharmaCytics submitted 3 new patents
PharmaCytics has submitted 3 new patents to support their Nutrient Drug Conjugate-technology (NDCt). It shows the continuous commitment to develop our ground-breaking Nutrient Drug Conjugate technology. The patents cover new nutrient drug conjugates and new linker technologies. All patents will support the work of PharmaCytics ultimately benefiting patients by making drugs more effective.
Read moreArdena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands
In partnership with GHO Capital, ARDENA announced a major €35 million investment for expansion across its European operations. The investment will future proof offerings for the biopharma and emerging biotechnology sectors and positions Ardena to become a leading global CDMO, offering end-to-end solutions spanning the full pharma development lifecycle.
Read more